| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 1.3K | 0.2% | 7.1% |
| Total Income | 1.3K | 0.2% | 7.1% |
| Expenditure | 1.2K | 8.0% | 2.9% |
| PBT | -3.00 | 98.0% | 94.8% |
| Net Profit | -28.00 | 54.8% | 800.0% |
| OPM | 7.42% | 8.28pp | 3.82pp |
| NPM | -2.19% | 2.67pp | 2.52pp |
| EPS | -0.08 | 55.6% | 900.0% |
Bausch + Lomb Announces Q3 2025 Results: Revenue $1.281 Billion
04 May 2026 · 4 May, 8:35 am
Summary
Bausch + Lomb announced its third-quarter 2025 financial results, with total revenue reaching $1.281 billion, a 7% increase compared to the same period in 2024. The company reported a GAAP net loss of $28 million. Adjusted EBITDA stood at $243 million. The company is updating its full-year 2025 Adjusted EBITDA excluding Acquired IPR&D guidance.
Key Highlights
- 1
Bausch + Lomb reported revenue of $1.281 billion for the third quarter of 2025.
- 2
The company's GAAP net loss attributable to Bausch + Lomb Corporation was $28 million.
- 3
Adjusted EBITDA was $243 million, with the same figure excluding acquired IPR&D.
- 4
Revenue grew by 7% as reported and 6% on a constant currency basis compared to Q3 2024.
- 5
Vision Care segment revenue increased by 8% to $736 million compared to the third quarter of 2024.
- 6
Pharmaceuticals segment revenue increased by 8% to $330 million compared to the third quarter of 2024.
- 7
Operating income increased by $52 million to $95 million for the third quarter of 2025.
Management Comments
Brent Saunders
“We’re delivering on the vision we laid out in 2023, with a base business engine that continues to hum and steady introduction of innovative products across categories,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our loaded and differentiated pipeline featuring clinical-stage programs will be on full display in just a few weeks at investor day.”
Informational and educational content only. Not investment advice.